Tepotinib is manufactured by which pharmaceutical company?

Tepotinib (Tepotinib) is a targeted therapy drug mainly used to treat patients with METexon14 skipping mutation (METex14 skipping mutation) non-small cell lung cancer (NSCLC) patients. The drug is developed and produced by the famous German pharmaceutical company Merck KGaA, Darmstadt, Germany. As an oral MET tyrosine kinase inhibitor, the launch of tepotinib is considered a major progress in the treatment of MET mutant lung cancer.

Merck is a multinational pharmaceutical and chemical company with far-reaching global influence, with a history of more than 350 years. The company continues to expand its innovative product line in the field of oncology, and tepotinib is one of the key results under its precision medicine strategy. Merck has incorporated genetic testing technology in the research and development process to better screen patients suitable for treatment with the drug, improve efficacy and reduce the risk of side effects.

Tepotinib was first approved in Japan in 2020, becoming the world's first targeted therapy drug approved for MET mutated lung cancer. Subsequently, the drug also received accelerated approval from the U.S. FDA and was launched in many European countries. This rapid cross-regional promotion further reflects Merck’s scientific research and commercial capabilities in the global market, and also provides more treatment options for patients around the world.

At present, tepotinib has gradually entered the routine treatment sequence in some countries and regions, but in mainland China, it has not yet been fully launched, and some patients need to obtain the drug through overseas channels. With the popularization of the concept of molecular targeted therapy, the application prospects of tepotinib are widely optimistic, and it is expected that the approval process will be completed faster in my country in the future, benefiting more lung cancer patients.

Reference materials:https://www.tepotinib.com/